Could Aeterna Zentaris Inc (NASDAQ:AEZS) See a Reversal After Less Sellers Came In?

September 14, 2018 - By Tyler Harlow

The stock of Aeterna Zentaris Inc (NASDAQ:AEZS) registered a decrease of 9.29% in short interest. AEZS’s total short interest was 415,800 shares in September as published by FINRA. Its down 9.29% from 458,400 shares, reported previously. With 55,200 shares average volume, it will take short sellers 8 days to cover their AEZS’s short positions.

The stock increased 0.95% or $0.0156 during the last trading session, reaching $1.6556. About 11,104 shares traded. Aeterna Zentaris Inc. (NASDAQ:AEZS) has declined 16.25% since September 14, 2017 and is downtrending. It has underperformed by 31.87% the S&P500.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company has market cap of $27.41 million. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It has a 18 P/E ratio. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology.

Aeterna Zentaris Inc. (NASDAQ:AEZS) Ratings Coverage

Among 2 analysts covering Aeterna Zentaris (NASDAQ:AEZS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeterna Zentaris has $300 highest and $300 lowest target. $3’s average target is 81.20% above currents $1.6556 stock price. Aeterna Zentaris had 3 analyst reports since March 29, 2018 according to SRatingsIntel. The company was maintained on Wednesday, May 9 by H.C. Wainwright. The stock of Aeterna Zentaris Inc. (NASDAQ:AEZS) earned “Buy” rating by H.C. Wainwright on Thursday, March 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.